Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the atm gene

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Lee, Jeeyun ^a   Sung, Chang Ohk ^a,c   Lee, Eui J ^b   Do, In Gu ^a   Kim, Hee Cheol ^a   Yoon, Seong Hyeon ^a   Lee, Woo Yong ^a   Chun, Ho Kyung ^a   Kim, Kyoung Mee ^a   Park, Young Suk ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Bupyeong gu   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BETA ACTIN; CELL CYCLE PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; KI 67 ANTIGEN; RNA 18S; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; ATM GENE; CANCER INHIBITION; CANCER SURVIVAL; CCNB1 GENE; CCND2 GENE; CDKN3 GENE; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; COLON BIOPSY; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE EXPRESSION; GENE OVEREXPRESSION; GTSE1 GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS POTENTIAL; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RBL2 GENE; REAL TIME POLYMERASE CHAIN REACTION; RECTUM BIOPSY; RECTUM CANCER; TUMOR GENE; COLORECTAL TUMOR; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; CELL CYCLE PROTEINS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84859260871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034456     Document Type: Article

References (44)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, et al. (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072.
2. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, et al. (2008) Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113: 2655-2664.
3. Hemminki K, Li X, (2001) Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92: 2204-2210.
4. Lepage C, Rachet B, Coleman MP, (2007) Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 132: 899-904.
5. Chan JA, Kulke MH, (2011) New Treatment Options for Patients with Advanced Neuroendocrine Tumors. Curr Treat Options Oncol.
6. Kloppel G, Perren A, Heitz PU, (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014: 13-27.
7. Solcia EKG, Sobin LH, (2000) World Health Organization International Histological Classification of Tumours. World Health Organization International Histological Classification of Tumours: 2nd ed New York, NY Springer.
8. Williams GT, (2007) Endocrine tumours of the gastrointestinal tract-selected topics. Histopathology 50: 30-41.
9. Fahy BN, Tang LH, Klimstra D, Wong WD, Guillem JG, et al. (2007) Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment. Ann Surg Oncol 14: 1735-1743.
10. Koura AN, Giacco GG, Curley SA, Skibber JM, Feig BW, et al. (1997) Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 79: 1294-1298.
11. Shields CJ, Tiret E, Winter DC, (2010) Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg 252: 750-755.
12. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, et al. (2010) Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34: 300-313.
13. Mitui M, Nahas SA, Du LT, Yang Z, Lai CH, et al. (2009) Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk. Hum Mutat 30: 12-21.
14. Matsuoka S, Huang M, Elledge SJ, (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282: 1893-1897.
15. Sterner JM, Dew-Knight S, Musahl C, Kornbluth S, Horowitz JM, (1998) Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol Cell Biol 18: 2748-2757.
16. Lavin MF, (2008) Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9: 759-769.
17. Lobrich M, Jeggo PA, (2007) The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 7: 861-869.
18. Taylor AM, Byrd PJ, (2005) Molecular pathology of ataxia telangiectasia. J Clin Pathol 58: 1009-1015.
19. Lee SW, Reimer CL, Fang L, Iruela-Arispe ML, Aaronson SA, (2000) Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol Cell Biol 20: 1723-1732.
20. De Falco G, Leucci E, Lenze D, Piccaluga PP, Claudio PP, et al. (2007) Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood 110: 1301-1307.
21. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS, (2002) ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 52: 606-613.
22. Cole J, Arlett CF, Green MH, Harcourt SA, Priestley A, et al. (1988) Comparative human cellular radiosensitivity: II. The survival following gamma-irradiation of unstimulated (G0) T-lymphocytes, T-lymphocyte lines, lymphoblastoid cell lines and fibroblasts from normal donors, from ataxia-telangiectasia patients and from ataxia-telangiectasia heterozygotes. Int J Radiat Biol 54: 929-943.
23. DahlBerg WK, Little JB, (1995) Response of dermal fibroblast cultures from patients with unusually severe responses to radiotherapy and from ataxia telangiectasia heterozygotes to fractionated radiation. Clin Cancer Res 1: 785-790.
24. Gatti RA, Tward A, Concannon P, (1999) Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 68: 419-423.
25. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870.
26. Bartek J, (2011) DNA damage response, genetic instability and cancer: from mechanistic insights to personalized treatment. Mol Oncol 5: 303-307.
27. Khanna KK, (2000) Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst 92: 795-802.
28. Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P, (2000) Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A 97: 2773-2778.
29. Stoppa-Lyonnet D, Soulier J, Lauge A, Dastot H, Garand R, et al. (1998) Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood 91: 3920-3926.
30. Zhang P, Bhakta KS, Puri PL, Newbury RO, Feramisco JR, et al. (2003) Association of ataxia telangiectasia mutated (ATM) gene mutation/deletion with rhabdomyosarcoma. Cancer Biol Ther 2: 87-91.
31. Zhang L, Jia G, Li WM, Guo RF, Cui JT, et al. (2004) Alteration of the ATM gene occurs in gastric cancer cell lines and primary tumors associated with cellular response to DNA damage. Mutat Res 557: 41-51.
32. Atencio DP, Iannuzzi CM, Green S, Stock RG, Bernstein JL, et al. (2001) Screening breast cancer patients for ATM mutations and polymorphisms by using denaturing high-performance liquid chromatography. Environ Mol Mutagen 38: 200-208.
33. Swift M, Morrell D, Massey RB, Chase CL, (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325: 1831-1836.
34. Mazumder Indra D, Mitra S, Roy A, Mondal RK, Basu PS, et al. (2011) Alterations of ATM and CADM1 in chromosomal 11q22.3-23.2 region are associated with the development of invasive cervical carcinoma. Hum Genet 130: 735-748.
35. Vorechovsky I, Rasio D, Luo L, Monaco C, Hammarstrom L, et al. (1996) The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res 56: 2726-2732.
36. Ai L, Vo QN, Zuo C, Li L, Ling W, et al. (2004) Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev 13: 150-156.
37. Kim WJ, Vo QN, Shrivastav M, Lataxes TA, Brown KD, (2002) Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene 21: 3864-3871.
38. Xie P, Li L, Xing G, Tian C, Yin Y, et al. (2011) ATM-mediated NuSAP phosphorylation induces mitotic arrest. Biochem Biophys Res Commun 404: 413-418.
39. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, et al. (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116: 4578-4587.
40. Williamson CT, Muzik H, Turhan AG, Zamo A, O'Connor MJ, et al. (2010) ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 9: 347-357.
41. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523.
42. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, et al. (2010) Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45: 234-243.
43. Modlin IM, Lye KD, Kidd M, (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934-959.
44. Soga J, (1998) Carcinoids of the colon and ileocecal region: a statistical evaluation of 363 cases collected from the literature. J Exp Clin Cancer Res 17: 139-148.